Terms: = Sarcomas AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
20 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of rare driving events in pediatric acute myeloid leukemia.
Noort S; Oosterwijk JV; Ma J; Garfinkle EAR; Nance S; Walsh M; Song G; Reinhardt D; Pigazzi M; Locatelli F; Hasle H; Abrahamsson J; Jarosova M; Kelaidi C; Polychronopoulou S; Van den Heuvel-Eibrink MM; Fornerod M; Gruber TA; Zwaan CM
Haematologica; 2023 Jan; 108(1):48-60. PubMed ID: 35899387
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcomes of Scanning Carbon-ion Radiotherapy for Soft Tissue Sarcoma of the Extremities.
Takakusagi Y; Serizawa I; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Katoh H; Hiruma T; Kamada T
Anticancer Res; 2022 Jul; 42(7):3701-3706. PubMed ID: 35790269
[TBL] [Abstract] [Full Text] [Related]
4. PET/MR fusion texture analysis for the clinical outcome prediction in soft-tissue sarcoma.
Zhao W; Huang X; Wang G; Guo J
Cancer Imaging; 2022 Jan; 22(1):7. PubMed ID: 35022071
[TBL] [Abstract] [Full Text] [Related]
5. Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.
Zhu YZ; Liu Y; Liao XW; Luo SS
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33851708
[TBL] [Abstract] [Full Text] [Related]
6. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.
Toulmonde M; Lucchesi C; Verbeke S; Crombe A; Adam J; Geneste D; Chaire V; Laroche-Clary A; Perret R; Bertucci F; Bertolo F; Bianchini L; Dadone-Montaudie B; Hembrough T; Sweet S; Kim YJ; Cecchi F; Le Loarer F; Italiano A
EBioMedicine; 2020 Dec; 62():103131. PubMed ID: 33254023
[TBL] [Abstract] [Full Text] [Related]
7. Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma.
Chen Y; Zhao B; Wang X
BMC Cancer; 2020 Oct; 20(1):1022. PubMed ID: 33087099
[TBL] [Abstract] [Full Text] [Related]
8. Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.
Nielsen B; Kleppe A; Hveem TS; Pradhan M; Syvertsen RA; Nesheim JA; Kristensen GB; Trovik J; Kerr DJ; Albregtsen F; Danielsen HE
J Natl Cancer Inst; 2018 Dec; 110(12):1400-1408. PubMed ID: 29684152
[TBL] [Abstract] [Full Text] [Related]
9. Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma.
Smida J; Xu H; Zhang Y; Baumhoer D; Ribi S; Kovac M; von Luettichau I; Bielack S; O'Leary VB; Leib-Mösch C; Frishman D; Nathrath M
Int J Cancer; 2017 Aug; 141(4):816-828. PubMed ID: 28494505
[TBL] [Abstract] [Full Text] [Related]
10. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of outcome after Chemotherapy-Based Treatment.
Hagleitner MM; Coenen MJ; Gelderblom H; Makkinje RR; Vos HI; de Bont ES; van der Graaf WT; Schreuder HW; Flucke U; van Leeuwen FN; Hoogerbrugge PM; Guchelaar HJ; te Loo DM
Clin Cancer Res; 2015 Aug; 21(15):3436-41. PubMed ID: 25829401
[TBL] [Abstract] [Full Text] [Related]
11. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas.
Szkandera J; Gerger A; Liegl-Atzwanger B; Absenger G; Stotz M; Friesenbichler J; Trajanoski S; Stojakovic T; Eberhard K; Leithner A; Pichler M
Int J Cancer; 2014 Jul; 135(2):362-70. PubMed ID: 24347236
[TBL] [Abstract] [Full Text] [Related]
12. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
Robertson S; Hyder O; Dodson R; Nayar SK; Poling J; Beierl K; Eshleman JR; Lin MT; Pawlik TM; Anders RA
Hum Pathol; 2013 Dec; 44(12):2768-73. PubMed ID: 24139215
[TBL] [Abstract] [Full Text] [Related]
13. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.
Posthumadeboer J; Piersma SR; Pham TV; van Egmond PW; Knol JC; Cleton-Jansen AM; van Geer MA; van Beusechem VW; Kaspers GJ; van Royen BJ; Jiménez CR; Helder MN
Br J Cancer; 2013 Oct; 109(8):2142-54. PubMed ID: 24064975
[TBL] [Abstract] [Full Text] [Related]
14. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract] [Full Text] [Related]
15. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.
Lagarde P; Pérot G; Kauffmann A; Brulard C; Dapremont V; Hostein I; Neuville A; Wozniak A; Sciot R; Schöffski P; Aurias A; Coindre JM; Debiec-Rychter M; Chibon F
Clin Cancer Res; 2012 Feb; 18(3):826-38. PubMed ID: 22167411
[TBL] [Abstract] [Full Text] [Related]
16. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.
Chibon F; Lagarde P; Salas S; Pérot G; Brouste V; Tirode F; Lucchesi C; de Reynies A; Kauffmann A; Bui B; Terrier P; Bonvalot S; Le Cesne A; Vince-Ranchère D; Blay JY; Collin F; Guillou L; Leroux A; Coindre JM; Aurias A
Nat Med; 2010 Jul; 16(7):781-7. PubMed ID: 20581836
[TBL] [Abstract] [Full Text] [Related]
17. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia.
Orvieto E; Furlanetto A; Laurino L; Dei Tos AP
Semin Diagn Pathol; 2001 Nov; 18(4):267-73. PubMed ID: 11757867
[TBL] [Abstract] [Full Text] [Related]
18. Liposarcoma: new entities and evolving concepts.
Dei Tos AP
Ann Diagn Pathol; 2000 Aug; 4(4):252-66. PubMed ID: 10982304
[TBL] [Abstract] [Full Text] [Related]
19. Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study.
Wang J; Coltrera MD; Gown AM
Cancer Res; 1994 Jan; 54(2):560-4. PubMed ID: 7903911
[TBL] [Abstract] [Full Text] [Related]
20. Histological investigation for comparison of cartilaginous tumors of unknown biological course with unequivocal chondrosarcomas.
Féaux de Lacroix W; Dietlein M; Schmidt J; Stützer H
Zentralbl Pathol; 1992 Nov; 138(5):339-43. PubMed ID: 1477083
[TBL] [Abstract] [Full Text] [Related]
